| Ticker: SLF | 200 Prospect Street | |
| Exchange: American Stock Exchange | Waltham, Massachusetts 02154 | |
| Industry: Manufacturing | (617) 647-3900 |
| Type of Shares: | Common Shares | Filing Date: | 5/17/96 | |
| U.S. Shares: | 1,300,000 | Offer Date: | 8/5/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $9.00 - $11.00 | |
| Primary Shares: | 1,300,000 | Offer Price: | $8.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.60 | |
| Offering Amount: | $13,000,000 | Selling: | $0.30 | |
| Expenses: | $900,000 | Reallowance: | $0.10 | |
| Shares Out After: | 13,040,133 |
| Manager | Tier | Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 640-6129 |
| Adams, Harkness & Hill | Co-manager | (617) 423-6688 |
| Dillon, Read & Co. Inc. | Co-manager | (212) 906-7000 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $7.24 | $2.47 | $1.34 | Assets: | $12.37 |
| Net Income: | -$10.10 | -$10.73 | -$0.91 | Liabilities: | $20.20 |
| EPS: | -$0.17 | -$0.99 | -$0.15 | Equity: | -$7.84 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a diversified manufacturing company. Selfcare is engaged in the development, manufacture and marketing of self-test diagnostic products for diabetes, women's health and infectious disease markets. Self-test diagnostic products allow individuals to obtain accurate information regarding various medical conditions on a confidential, non-prescription basis, without the expense, inconvenience and delay associated with physician visits or testing laboratories. This information gives individuals greater control over their health and their lives, allowing them to make informed decisions and take action to protect their health, alone or in consultation with healthcare professionals. The Company's existing and planned products are targeted at the two largest existing markets for self-care diagnostics, diabetes management and women's health, as well as the emerging market for self tests for infectious diseases and agents, including human immunodeficiency viruses. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used to repay indebtedness, to fund a portion of the consideration payable for the acquisition of a majority interest in Orgencis; to fund research and development; and for working capital and other general corporate purposes, including possible acquisitions. |
©1996 IPO Data Systems, Inc. - All rights reserved.